Kura Oncology, Inc. (KURA): who owns it and who trades it
As of Nov 16, 2026, KURA insiders reported 34 open-market sales worth $3.3M and 4 purchases worth $3.9M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mollie Leoni (Chief Medical Officer), with $1.3M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kura Oncology
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KURA
218 funds and institutions reported KURA shares worth $962M at the end of Q2 2026, about 99% of the company. The largest holder is BlackRock, Inc. with 11.9%.
Funds and institutions (13F) 99%Everyone else 1%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 10.51M | 11.90% | $115M | +9% |
| Montanova Capital, LLC | 8.58M | 9.71% | $94.1M | No change |
| Bvf Inc | 8.45M | 9.56% | $92.7M | No change |
| State Street Corp | 5.33M | 6.03% | $58.5M | +18% |
| Vanguard Capital Management LLC | 3.92M | 4.43% | $43M | +3% |
| Armistice Capital, LLC | 3.68M | 4.16% | $40.3M | -2% |
| AQR Capital Management LLC | 3.13M | 3.54% | $34.3M | +47% |
| Goldman Sachs Group Inc | 2.27M | 2.56% | $24.8M | +58% |
| Geode Capital Management, LLC | 2.23M | 2.52% | $24.5M | +10% |
| Alethea Capital Management, LLC | 2.17M | 2.45% | $23.8M | +42% |
| Prosight Management, LP | 2.02M | 2.29% | $22.2M | -40% |
| Deep Track Capital, LP | 1.98M | 2.24% | $21.7M | -25% |
| Renaissance Technologies LLC | 1.66M | 1.88% | $18.3M | +5% |
| Arrowstreet Capital, Limited Partnership | 1.41M | 1.60% | $15.5M | – |
| Vanguard Portfolio Management LLC | 1.33M | 1.51% | $14.6M | +8% |
| Nan Fung Trinity (hk) Ltd | 1.17M | 1.33% | $12.9M | +10% |
| Qube Research & Technologies Ltd | 1.17M | 1.32% | $12.8M | -29% |
| Dimensional Fund Advisors LP | 1.17M | 1.32% | $12.8M | -18% |
| Bank of America Corp | 1.16M | 1.31% | $12.7M | -6% |
| Morgan Stanley | 1.16M | 1.31% | $12.7M | -0% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KURA insiders reported $3.9M of open-market purchases and $3.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Troy Edward Wilson | CEO | Purchase | 101,119 | $7.42 | $750K | Form 4 |
| Nov 13, 2026 | Troy Edward Wilson | CEO | Purchase | 98,881 | $7.63 | $754K | Form 4 |
| Sep 29, 2026 | Kathleen Ford | Chief Operating Officer | Sale | 3,668 | $10.75 | $39.4K | Form 4 |
| Sep 29, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 28,802 | $10.75 | $310K | Form 4 |
| Sep 29, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 15,430 | $10.75 | $166K | Form 4 |
| Sep 28, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 8,442 | $10.50 | $88.6K | Form 4 |
| Sep 28, 2026 | Kathleen Ford | Chief Operating Officer | Sale | 6,906 | $10.50 | $72.5K | Form 4 |
| Sep 28, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 12,448 | $10.50 | $131K | Form 4 |
| Sep 28, 2026 | Thomas James Doyle | Vice president | Sale | 4,607 | $10.50 | $48.4K | Form 4 |
| Sep 28, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 9,020 | $10.50 | $94.7K | Form 4 |
| Sep 28, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 8,000 | $10.56 | $84.5K | Form 4 |
| Sep 24, 2026 | Francis Burrows | Chief Scientific Officer | Sale | 20,726 | $10.83 | $224K | Form 4 |
| Aug 24, 2026 | Troy Edward Wilson | CEO | Purchase | 100,000 | $12.39 | $1.2M | Form 4 |
| Aug 21, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 4,345 | $11.89 | $51.7K | Form 4 |
| Aug 19, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 31,487 | $12.63 | $398K | Form 4 |
| Aug 17, 2026 | Troy Edward Wilson | CEO | Purchase | 100,000 | $11.12 | $1.1M | Form 4 |
| Jun 18, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 84,929 | $9.82 | $834K | Form 4 |
| May 21, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 10,000 | $11.00 | $110K | Form 4 |
| May 19, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 339 | $9.21 | $3.1K | Form 4 |
| May 19, 2026 | Kathleen Ford | Chief Operating Officer | Sale | 2,257 | $9.08 | $20.5K | Form 4 |
| May 18, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 2,256 | $9.38 | $21.2K | Form 4 |
| Jan 27, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 1,572 | $8.46 | $13.3K | Form 4 |
| Jan 27, 2026 | Brian T. Powl | Chief Commercial Officer | Sale | 4,842 | $8.46 | $41K | Form 4 |
| Jan 27, 2026 | Francis Burrows | Chief Scientific Officer | Sale | 1,311 | $8.46 | $11.1K | Form 4 |
| Jan 27, 2026 | Kathleen Ford | Chief Operating Officer | Sale | 1,813 | $8.46 | $15.3K | Form 4 |
| Jan 27, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 1,341 | $8.46 | $11.3K | Form 4 |
| Jan 27, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 951 | $8.46 | $8K | Form 4 |
| Jan 27, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 3,655 | $8.46 | $30.9K | Form 4 |
| Jan 27, 2026 | Mollie Leoni | Chief Medical Officer | Sale | 2,233 | $8.46 | $18.9K | Form 4 |
| Jan 27, 2026 | Thomas James Doyle | Vice president | Sale | 1,114 | $8.46 | $9.4K | Form 4 |
| Jan 27, 2026 | Thomas James Doyle | Vice president | Sale | 695 | $8.46 | $5.9K | Form 4 |
| Jan 27, 2026 | Thomas James Doyle | Vice president | Sale | 2,226 | $8.46 | $18.8K | Form 4 |
| Jan 27, 2026 | Thomas James Doyle | Vice president | Sale | 881 | $8.46 | $7.5K | Form 4 |
| Jan 27, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 4,777 | $8.46 | $40.4K | Form 4 |
| Jan 27, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 2,335 | $8.46 | $19.8K | Form 4 |
| Jan 27, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sale | 4,096 | $8.46 | $34.7K | Form 4 |
| Dec 18, 2025 | Francis Burrows | Chief Scientific Officer | Sale | 23,726 | $9.78 | $232K | Form 4 |
| Dec 9, 2025 | Faheem Hasnain | Director | Sale | 10,000 | $10.98 | $110K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Troy Edward Wilson | President and CEO, Director | $3.9M | – | Nov 16, 2026 |
| Mollie Leoni | Chief Medical Officer | – | $1.3M | Sep 29, 2026 |
| Teresa Brophy Bair | Chief Legal Officer | – | $602K | Sep 28, 2026 |
| Brian T. Powl | Chief Commercial Officer | – | $564K | Sep 29, 2026 |
| Francis Burrows | Chief Scientific Officer | – | $468K | Sep 24, 2026 |
| Kathleen Ford | Chief Operating Officer | – | $148K | Sep 29, 2026 |
| Faheem Hasnain | Director | – | $110K | Dec 9, 2025 |
| Thomas James Doyle | SVP, Finance & Accounting | – | $90K | Sep 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KURA short interest
High short interest. 14.2% of KURA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.64M KURA shares were sold short, 14.2% of the shares outstanding, down 11.7% from the report before. At the average daily volume of 1.61M shares, buying them all back would take about 7.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.64M | 14.21% | -12% | 1.61M | 7.9 |
| Oct 15, 2026 | 14.32M | 16.10% | -1% | 1.67M | 8.6 |
| Sep 30, 2026 | 14.42M | 16.21% | -3% | 1.86M | 7.7 |
| Sep 15, 2026 | 14.82M | 16.66% | +10% | 1.69M | 8.8 |
| Aug 31, 2026 | 13.42M | 15.08% | +2% | 2.80M | 4.8 |
| Aug 14, 2026 | 13.12M | 14.75% | -0% | 1.49M | 8.8 |
| Jul 31, 2026 | 13.16M | 14.90% | -4% | 1.11M | 11.8 |
| Jul 15, 2026 | 13.73M | 15.55% | -9% | 1.78M | 7.7 |
| Jun 30, 2026 | 15.09M | 17.09% | +3% | 1.76M | 8.6 |
| Jun 15, 2026 | 14.60M | 16.53% | +7% | 1.99M | 7.3 |
| May 29, 2026 | 13.59M | 15.39% | -13% | 2.55M | 5.3 |
| May 15, 2026 | 15.64M | 17.71% | +1% | 1.37M | 11.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kura Oncology company events
Kura Oncology filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 9, 2026AnnouncementSubsidiary Financing Kura Oncology, Inc. formed a wholly owned subsidiary, Caspian Therapeutics, Inc., to focus on the development of next-generation menin inhibitors for the treatment of diabetes and other cardiometabolic diseases. Filing
- Sep 8, 2026LeadershipThe Board of Directors of Kura Oncology, Inc. appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such… Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 29, 2026LeadershipKura Oncology, Inc. entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer to, among other things, modify certain severance provisions. Filing
- Jun 4, 2026LeadershipOur Board of Directors, upon the recommendation of the Compensation Committee of the Board, amended the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan, in each case subject to stockholder approval, to, among other things, increase the… Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 29, 2026RulesChanged its bylaws or articles. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 2, 2025AnnouncementKura Oncology, Inc. announced the first U.S. commercial sale of KOMZIFTI ™ (ziftomenib) has been completed. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kura Oncology financials
Famous investors that hold KURA
5 of the 50 well-known investors we track reported holding KURA in their latest 13F filing. The largest position is Jim Simons's, worth $21.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.01M | $21.5M | 0.0% | +21% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 680,119 | $7.3M | 0.0% | +107% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 565,300 | $6.1M | 0.0% | -10% |
| Israel Englander · Millennium Management | Q3 2026 | 358,402 | $3.8M | 0.0% | -50% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 42,940 | $460K | 0.0% | -1% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named KURA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 3.9% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 3.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.9% |
Questions about Kura Oncology, Inc. (KURA) stock
Who owns the most KURA stock?
The largest reported owner of Kura Oncology, Inc. (KURA) is BlackRock, Inc., with 11.9% of the company. In total, 218 funds and institutions reported holding KURA at the end of Q2 2026, together about 99% of the shares. See the largest owners.
Are KURA insiders buying or selling?
In the last 12 months, KURA insiders reported 4 open-market purchases worth $3.9M and 34 sales worth $3.3M. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in KURA?
As of Oct 30, 2026, 12.64M KURA shares were sold short, 14.2% of the shares outstanding, down 11.7% from the report before. At the average daily volume of 1.61M shares, buying them all back would take about 7.9 trading days (days to cover). See the history.
Which famous investors hold KURA?
5 of the 50 well-known investors we track reported KURA in their latest 13F filing, including Jim Simons, Ken Griffin, Ken Fisher. The largest position is worth $21.5M. See all holders.
Executive pay
Kura Oncology's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, down 24% from $6.2M the year before. In the last 12 months, Kura Oncology's executives and directors bought $3.9M of stock on the open market and sold $3.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.